company background image
CYCN

Cyclerion TherapeuticsNasdaqGS:CYCN Stock Report

Market Cap

US$120.7m

7D

-0.4%

1Y

3.3%

Updated

21 Oct, 2021

Data

Company Financials +
CYCN fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

CYCN Overview

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases.

Price History & Performance

Summary of all time highs, changes and price drops for Cyclerion Therapeutics
Historical stock prices
Current Share PriceUS$2.79
52 Week HighUS$2.08
52 Week LowUS$6.90
Beta1.86
1 Month Change-13.89%
3 Month Change-32.45%
1 Year Change3.33%
3 Year Changen/a
5 Year Changen/a
Change since IPO-80.75%

Recent News & Updates

Shareholder Returns

CYCNUS BiotechsUS Market
7D-0.4%0.4%2.6%
1Y3.3%17.1%31.1%

Return vs Industry: CYCN underperformed the US Biotechs industry which returned 17.8% over the past year.

Return vs Market: CYCN underperformed the US Market which returned 31.5% over the past year.

Price Volatility

Is CYCN's price volatile compared to industry and market?
CYCN volatility
CYCN Beta1.86
Industry Beta0.98
Market Beta1

Stable Share Price: CYCN is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: CYCN's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
201834Peter Hechthttps://www.cyclerion.com

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its product candidates include CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase II trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes (MELAS) and Alzheimer's disease with vascular pathology (ADv); Olinciguat, an orally administered vascular soluble guanylate cyclase stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Cyclerion Therapeutics Fundamentals Summary

How do Cyclerion Therapeutics's earnings and revenue compare to its market cap?
CYCN fundamental statistics
Market CapUS$120.74m
Earnings (TTM)-US$67.62m
Revenue (TTM)US$3.60m

33.6x

P/S Ratio

-1.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CYCN income statement (TTM)
RevenueUS$3.60m
Cost of RevenueUS$40.13m
Gross Profit-US$36.53m
ExpensesUS$31.09m
Earnings-US$67.62m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-1.56
Gross Margin-1,016.16%
Net Profit Margin-1,880.97%
Debt/Equity Ratio5.4%

How did CYCN perform over the long term?

See historical performance and comparison

Valuation

Is Cyclerion Therapeutics undervalued compared to its fair value and its price relative to the market?

1.85x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CYCN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CYCN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CYCN is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: CYCN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CYCN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CYCN is good value based on its PB Ratio (1.9x) compared to the US Biotechs industry average (2.9x).


Future Growth

How is Cyclerion Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

-24.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CYCN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CYCN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CYCN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CYCN's revenue is expected to decline over the next 3 years (-33.6% per year).

High Growth Revenue: CYCN's revenue is forecast to decline over the next 3 years (-33.6% per year).


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CYCN's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Cyclerion Therapeutics performed over the past 5 years?

3.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CYCN is currently unprofitable.

Growing Profit Margin: CYCN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CYCN is unprofitable, but has reduced losses over the past 5 years at a rate of 3.3% per year.

Accelerating Growth: Unable to compare CYCN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CYCN is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).


Return on Equity

High ROE: CYCN has a negative Return on Equity (-103.68%), as it is currently unprofitable.


Financial Health

How is Cyclerion Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: CYCN's short term assets ($73.0M) exceed its short term liabilities ($10.5M).

Long Term Liabilities: CYCN has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: CYCN's debt to equity ratio (5.4%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if CYCN's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CYCN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CYCN has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 3% each year.


Dividend

What is Cyclerion Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CYCN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CYCN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CYCN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CYCN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CYCN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.8yrs

Average management tenure


CEO

Peter Hecht (57 yo)

2.5yrs

Tenure

US$365,993

Compensation

Dr. Peter M. Hecht, Ph D., served as the Chief Executive Officer of Ironwood Pharmaceuticals, Inc. since 1998 until April 1, 2019. Dr. Hecht is Chief Executive Officer and Director of Cyclerion Therapeutic...


CEO Compensation Analysis

Compensation vs Market: Peter's total compensation ($USD365.99K) is below average for companies of similar size in the US market ($USD543.98K).

Compensation vs Earnings: Peter's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: CYCN's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: CYCN's board of directors are not considered experienced ( 2.5 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.6%.


Top Shareholders

Company Information

Cyclerion Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Cyclerion Therapeutics, Inc.
  • Ticker: CYCN
  • Exchange: NasdaqGS
  • Founded: 2018
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$120.742m
  • Shares outstanding: 43.28m
  • Website: https://www.cyclerion.com

Number of Employees


Location

  • Cyclerion Therapeutics, Inc.
  • 301 Binney Street
  • Cambridge
  • Massachusetts
  • 2142
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/21 23:08
End of Day Share Price2021/10/21 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.